DETECTION OF CHIMERIC TRANSCRIPTS OF THE IMMUNOGLOBULIN HEAVY-CHAIN AND BCL6 GENES BY REVERSE-TRANSCRIPTASE POLYMERASE-CHAIN-REACTION IN B-CELL NON-HODGKINS-LYMPHOMAS

Citation
N. Kawamata et al., DETECTION OF CHIMERIC TRANSCRIPTS OF THE IMMUNOGLOBULIN HEAVY-CHAIN AND BCL6 GENES BY REVERSE-TRANSCRIPTASE POLYMERASE-CHAIN-REACTION IN B-CELL NON-HODGKINS-LYMPHOMAS, British Journal of Haematology, 100(3), 1998, pp. 484-489
Citations number
23
Categorie Soggetti
Hematology
ISSN journal
00071048
Volume
100
Issue
3
Year of publication
1998
Pages
484 - 489
Database
ISI
SICI code
0007-1048(1998)100:3<484:DOCTOT>2.0.ZU;2-N
Abstract
T(3;14)(q27;q32) is frequently detected in B-cell non-Hodgkin's lympho mas, especially the diffuse large cell type and the follicular type. T he BCL6 gene encoding a putative transcriptional factor which resides on 3q27 rearranges to the immunoglobulin heavy chain (IgH) gene on 14q 32 in this chromosomal translocation. The upstream regulatory region o f the BCL6 gene is replaced by the IgH gene. Deregulation of the BCL6 gene may contribute to tumourigenesis of these diseases. The rearrange ment between the IgH and BCL6 genes generates chimaeric transcripts in which the joining (J) region of the IgH gene fuses to exon 3 of the B CL6 gene. We established a method to detect these chimaeric transcript s by reverse transcriptase polymerase chain reaction (RT-PCR) using th e consensus sequence of the J region and the sequence of exon 3 of the BCL6 gene as primers, Using the semi-nested RT-PCR method and a cell Line carrying t(3;14)(q27:q32), we detected one lymphoma cell among 10 000 background cells. We detected these chimaeric transcripts in two o ut of 13 clinical samples by this method. This method can detect t(3;1 4)(q27;q32) easily, whereas this alteration is frequently overlooked b y routine karyotype analysis, Since this technique is sensitive enough to detect a small number of lymphoma cells with this genetic abnormal ity, it could be employed to detect contaminating lymphoma cells in bo ne marrow and peripheral blood and minimal residual diseases.